Here are the staff publications for February 2022.
Compiled by the Health Sciences Library (RMH, RWH, PMCC & Victorian Mental Health) 1st March 2022.
1. Antill Y, Buchanan DD, Scott CL. Mismatch repair and clinical response to immune checkpoint inhibitors in endometrial cancer. Cancer 2022;128:1157-61.
2. Au L, Hatipoglu E, Robert de Massy M, Litchfield K, Beattie G, Rowan A, Schnidrig D, Thompson R, Byrne F, Horswell S, Fotiadis N, Hazell S, Nicol D, Shepherd STC, Fendler A, Mason R, Del Rosario L, Edmonds K, Lingard K, Sarker S, Mangwende M, Carlyle E, Attig J, Joshi K, Uddin I, Becker PD, Sunderland MW, Akarca A, Puccio I, Yang WW, Lund T, Dhillon K, Vasquez MD, Ghorani E, Xu H, Spencer C, López JI, Green A, Mahadeva U, Borg E, Mitchison M, Moore DA, Proctor I, Falzon M, Pickering L, Furness AJS, Reading JL, Salgado R, Marafioti T, Jamal-Hanjani M, Kassiotis G, Chain B, Larkin J, Swanton C, Quezada SA, Turajlic S. Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. Cancer Cell 2021;39:1497-518.e11.
3. Banerjee AT, Landry M, Zawi M, Childerhose D, Stephens N, Shafique A, Price J. A Pilot Examination of a Mosque-Based Physical Activity Intervention for South Asian Muslim Women in Ontario, Canada. J Immigr Minor Health 2017;19:349-57.
4. Bartl AJ, Mahoney M, Hennon MW, Yendamuri S, Videtic GMM, Stephans KL, Siva S, Farrugia MK, Ma SJ, Singh AK. Systematic Review of Single-Fraction Stereotactic Body Radiation Therapy for Early Stage Non-Small-Cell Lung Cancer and Lung Oligometastases: How to Stop Worrying and Love One and Done. Cancers (Basel) 2022;14.
5. Bishop MR, Dickinson M, Purtill D, Barba P, Santoro A, Hamad N, Kato K, Sureda A, Greil R, Thieblemont C, Morschhauser F, Janz M, Flinn I, Rabitsch W, Kwong YL, Kersten MJ, Minnema MC, Holte H, Chan EHL, Martinez-Lopez J, Muller AMS, Maziarz RT, McGuirk JP, Bachy E, Le Gouill S, Dreyling M, Harigae H, Bond D, Andreadis C, McSweeney P, Kharfan-Dabaja M, Newsome S, Degtyarev E, Awasthi R, Del Corral C, Andreola G, Masood A, Schuster SJ, Jager U, Borchmann P, Westin JR. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. N Engl J Med 2022;386:629-39.
6. Blombery P, Lew TE, Dengler MA, Thompson ER, Lin VS, Chen X, Nguyen T, Panigrahi A, Handunnetti SM, Carney DA, Westerman DA, Tam CS, Adams JM, Wei AH, Huang DCS, Seymour JF, Roberts AW, Anderson MA. Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL. Blood 2022;139:1198-207.
7. Broske AE, Korfi K, Belousov A, Wilson S, Ooi CH, Bolen CR, Canamero M, Alcaide EG, James I, Piccione EC, Carlile DJ, Dimier N, Umana P, Bacac M, Weisser M, Dickinson M. Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma. Blood Adv 2022;6:1025-37.
8. Cochrane T, Enrico A, Gomez-Almaguer D, Hadjiev E, Lech-Maranda E, Masszi T, Nikitin E, Robak T, Weinkove R, Wu SJ, Sail KR, Pesko J, Pai M, Komlosi V, Anderson MA. Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 3b VENICE II trial. Leuk Lymphoma 2022;63:304-14.
9. Cribb BI, Kong J, McCormick J, Warrier SK, Heriot AG. Functional outcomes after lateral pelvic lymph node dissection for rectal cancer: a systematic review and meta-analysis. Int J Colorectal Dis 2022;37:583-95.
10. Cull G, Burger JA, Opat S, Gottlieb D, Verner E, Trotman J, Marlton P, Munoz J, Johnston P, Simpson D, Stern JC, Prathikanti R, Wu K, Novotny W, Huang J, Tam CS. Zanubrutinib for treatment-naive and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study. Br J Haematol 2022;196:1209-18.
11. Curigliano G, Mueller V, Borges V, Hamilton E, Hurvitz S, Loi S, Murthy R, Okines A, Paplomata E, Cameron D, Carey LA, Gelmon K, Hortobagyi GN, Krop I, Loibl S, Pegram M, Slamon D, Ramos J, Feng W, Winer E. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. Ann Oncol 2022;33:321-9.
12. Curtis AR, Livingstone KM, Daly RM, Marchese LE, Kiss N. Associations between Dietary Patterns and Malnutrition, Low Muscle Mass and Sarcopenia in Adults with Cancer: A Scoping Review. Int J Environ Res Public Health 2022;19.
13. Deftereos I, Hitch D, Butzkueven S, Carter V, Fetterplace K, Fox K, Ottaway A, Pierce K, Steer B, Varghese J, Kiss N, Yeung JM. Implementing a standardised perioperative nutrition care pathway in upper gastrointestinal cancer surgery: a mixed-methods analysis of implementation using the Consolidated Framework for Implementation Research. BMC Health Serv Res 2022;22:256.
14. Feehan DD, Jamil K, Polyak MJ, Ogbomo H, Hasell M, Li SS, Xiang RF, Parkins M, Trapani JA, Harrison JJ, Mody CH. Natural killer cells kill extracellular Pseudomonas aeruginosa using contact-dependent release of granzymes B and H. PLoS Pathog 2022;18:e1010325.
15. Garnier R, Nouyrigat E, Benoit P, Goullé JP, Granon C, Manel J, Manouchehri N, Mathieu-Huart A, Nisse P, Normand JC, Ronga-Pézeret S, Roulet A, Simon F, Gabach P, Tournoud C, Augé G, Barbillon A, Boudet C, Bourgeat M, Droissart-Long A, El Balkhi S, Franchitto N, Glaizal M, Glorennec P, Gnansia E, Haufroid V, Breurec JY, Cambier P, Carlier P, Carretier J, Chanaud D, Charrière A, Clinard F, Dereure O, Kleinlogel S, Labadie M, Laporte R, Heilier JF, Javelaud B, Lefranc A, Lelièvre B, Lucas D, Marot F, Mathieu O, Nesslany F, Nikolova-Pavageau N, Nisse C, Peronnet K, Puskarczyk E, Quénel P, Rauzier-Jaoul MC, Roussel H, Sadeg N, Sapori JM, Sauvant-Rochat MP, Verdun-Esquer C, Veyer K, Villa A, Vircondelet S. Dépistage, prise en charge et suivi des personnes potentiellement surexposées à l’arsenic inorganique du fait de leur lieu de résidence. Archives des Maladies Professionnelles et de l'Environnement 2020;81:770-96.
16. Gee G, Sheridan S, Charles L, Dayne L, Joyce L, Stevens J, Paradies Y, Hulbert C, Haslam N, Thorpe R, Thorpe L, Thorpe A, Stewart P, Austin L, Lyons L, Belfrage M, Warber R, Paxton A, Thompson L. The Her Tribe and His Tribe Aboriginal-Designed Empowerment Programs. Int J Environ Res Public Health 2022;19.
17. Goh PK, Wiede F, Zeissig MN, Britt KL, Liang S, Molloy T, Goode N, Xu R, Loi S, Muller M, Humbert PO, McLean C, Tiganis T. PTPN2 elicits cell autonomous and non-cell autonomous effects on antitumor immunity in triple-negative breast cancer. Sci Adv 2022;8:eabk3338.
18. Hadjiioannou I, Wong K, Lindup H, Mayes J, Castle E, Greenwood S. Test-Retest Reliability for Physical Function Measures in Patients with Chronic Kidney Disease. J Ren Care 2020;46:25-34.
19. Ivanova ME, Lukoyanova N, Malhotra S, Topf M, Trapani JA, Voskoboinik I, Saibil HR. The pore conformation of lymphocyte perforin. Sci Adv 2022;8:eabk3147.
20. Kennedy OJ, Kicinski M, Valpione S, Gandini S, Suciu S, Blank CU, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, van Akkooi ACJ, Robert C, Eggermont AMM, Lorigan P, Mandala M. Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma. Eur J Cancer 2022;165:97-112.
21. Khaw P, Do V, Lim K, Cunninghame J, Dixon J, Vassie J, Bailey M, Johnson C, Kahl K, Gordon C, Cook O, Foo K, Fyles A, Powell M, Haie-Meder C, D'Amico R, Bessette P, Mileshkin L, Creutzberg CL, Moore A. Radiotherapy Quality Assurance in the PORTEC-3 (TROG 08.04) Trial. Clin Oncol (R Coll Radiol) 2022;34:198-204.
22. Larach JT, Flynn J, Wright T, Rajkomar AKS, McCormick JJ, Kong J, Smart PJ, Heriot AG, Warrier SK. Robotic complete mesocolic excision versus conventional robotic right colectomy for right-sided colon cancer: a comparative study of perioperative outcomes. Surg Endosc 2022;36:2113-20.
23. Lawrentschuk N. Editorial Comment. J Urol 2022;207:580.
24. Lickliter JD, Voskoboynik M, Mileshkin L, Gan HK, Kichenadasse G, Zhang K, Zhang M, Tang Z, Millward M. Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours. Br J Cancer 2022;126:576-85.
25. Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, Ghobadi A, Rapoport AP, McGuirk J, Pagel JM, Munoz J, Farooq U, van Meerten T, Reagan PM, Sureda A, Flinn IW, Vandenberghe P, Song KW, Dickinson M, Minnema MC, Riedell PA, Leslie LA, Chaganti S, Yang Y, Filosto S, Shah J, Schupp M, To C, Cheng P, Gordon LI, Westin JR, All Z-I, Contributing Kite M. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N Engl J Med 2022;386:640-54.
26. MacManus M, Hegi-Johnson F. Overcoming immunotherapy resistance in NSCLC. Lancet Oncol 2022;23:191-3.
27. Malorni L, Tyekucheva S, Hilbers FS, Ignatiadis M, Neven P, Colleoni M, Henry S, Ballestrero A, Bonetti A, Jerusalem G, Papadimitriou K, Bernardo A, Seles E, Duhoux FP, MacPherson IR, Thomson A, Davies DM, Bergqvist M, Migliaccio I, Gebhart G, Zoppoli G, Bliss JM, Benelli M, McCartney A, Kammler R, De Swert H, Ruepp B, Fumagalli D, Maibach R, Cameron D, Loi S, Piccart M, Regan MM. Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant. Eur J Cancer 2022;164:39-51.
28. Mascarenhas J, Passamonti F, Burbury K, El-Galaly TC, Gerds A, Gupta V, Higgins B, Wonde K, Jamois C, Kovic B, Huw LY, Katakam S, Maffioli M, Mesa R, Palmer J, Bellini M, Ross DM, Vannucchi AM, Yacoub A. The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study. Blood Adv 2022;6:1162-74.
29. Mato AR, Davids MS, Sharman J, Roeker LE, Kay N, Kater AP, Rogers K, Thompson MC, Rhodes J, Goy A, Skarbnik A, Schuster SJ, Tam CS, Eyre TA, O'Brien S, Nabhan C, Lamanna N, Sun C, Shadman M, Pagel JM, Ujjani C, Brander D, Coombs CC, Jain N, Cheah CY, Brown JR, Seymour JF, Woyach JA. Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: "What's Past Is Prologue" (Shakespeare). Clin Cancer Res 2022;28:603-8.
30. McDowell L, Bossi P. The Burning Question: Prophylactic Gabapentin for Mucositis-Related Pain in Patients Undergoing Chemoradiation Therapy for Head and Neck Cancer? Int J Radiat Oncol Biol Phys 2022;112:938-41.
31. O'Malley DM, Bariani GM, Cassier PA, Marabelle A, Hansen AR, De Jesus Acosta A, Miller WH, Jr., Safra T, Italiano A, Mileshkin L, Xu L, Jin F, Norwood K, Maio M. Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study. J Clin Oncol 2022;40:752-61.
32. Parker A, Dash S, Bourke M, Patten R, Craike M, Baldwin P, Hosking W, Levinger I, Apostolopoulos V, de Courten M, Sharples J, Naslund M, Stavropoulos V, Woessner M, Sonn C, Stansen C, Pascoe M. A Brief, Daily, Online Mental Health and Well-being Intervention for University Staff During the COVID-19 Pandemic: Program Description and Outcomes Using a Mixed Methods Design. JMIR Form Res 2022;6:e35776.
33. Polese J, da Silva S, Faria-Fortini I, Faria C, Teixeira-Salmela L. Duke Activity Status Index cut-off scores for assessing functional capacity after stroke. Disabil Rehabil 2021;43:713-7.
34. Rambhatla JS, Tonkin-Hill GQ, Takashima E, Tsuboi T, Noviyanti R, Trianty L, Sebayang BF, Lampah DA, Marfurt J, Price RN, Anstey NM, Papenfuss AT, Damelang T, Chung AW, Duffy MF, Rogerson SJ. Identifying Targets of Protective Antibodies against Severe Malaria in Papua, Indonesia, Using Locally Expressed Domains of Plasmodium falciparum Erythrocyte Membrane Protein 1. Infect Immun 2022;90:e0043521.
35. Rowlands CF, Taylor A, Rice G, Whiffin N, Hall HN, Newman WG, Black GCM, O'Keefe RT, Hubbard S, Douglas AGL, Baralle D, Briggs TA, Ellingford JM. MRSD: A quantitative approach for assessing suitability of RNA-seq in the investigation of mis-splicing in Mendelian disease. Am J Hum Genet 2022;109:210-22.
36. Serova M, Andreev D, Giverts I, Sazonova Y, Svet A, Kuklina M, Sedov V, Syrkin A, Saner H. A new algorithm for optimization of rate-adaptive pacing improves exercise tolerance in patients with HFpEF. Pacing Clin Electrophysiol 2020;43:223-33.
37. Seymour JF. Is BTKi or BCL2i preferable as first novel therapy in patients with CLL? The case for BCL2i. Blood Adv 2022;6:1365-70.
38. Solomon BJ, Loong HH, Summers Y, Thomas ZM, French P, Lin BK, Sashegyi A, Wolf J, Yang JC, Drilon A. Correlation between treatment effects on response rate and progression-free survival and overall survival in trials of targeted therapies in molecularly enriched populations. ESMO Open 2022;7:100398.
39. Tam CS, Dimopoulos M, Garcia-Sanz R, Trotman J, Opat S, Roberts AW, Owen R, Song Y, Xu W, Zhu J, Li J, Qiu L, D'Sa S, Jurczak W, Cull G, Marlton P, Gottlieb D, Munoz J, Phillips T, Du C, Ji M, Zhou L, Guo H, Zhu H, Chan WY, Cohen A, Novotny W, Huang J, Tedeschi A. Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies. Blood Adv 2022;6:1296-308.
40. Tewari KS, Monk BJ, Vergote I, Miller A, de Melo AC, Kim HS, Kim YM, Lisyanskaya A, Samouëlian V, Lorusso D, Damian F, Chang CL, Gotovkin EA, Takahashi S, Ramone D, Pikiel J, Maćkowiak-Matejczyk B, Guerra Alía EM, Colombo N, Makarova Y, Rischin D, Lheureux S, Hasegawa K, Fujiwara K, Li J, Jamil S, Jankovic V, Chen CI, Seebach F, Weinreich DM, Yancopoulos GD, Lowy I, Mathias M, Fury MG, Oaknin A. Survival with Cemiplimab in Recurrent Cervical Cancer. N Engl J Med 2022;386:544-55.
41. Trubiano JA, Vogrin S, Copaescu A, Nasra M, Douglas A, Holmes NE, Chua KYL. Direct oral penicillin challenge for penicillin allergy delabeling as a health services intervention: A multicenter cohort study. Allergy 2022;77:1038-42.
42. Wijeysundera DN, Beattie WS, Hillis GS, Abbott TEF, Shulman MA, Ackland GL, Mazer CD, Myles PS, Pearse RM, Cuthbertson BH, Measurement of Exercise Tolerance before Surgery Study I, Myles PS, Shulman MA, Wallace S, Farrington C, Thompson B, Ellis M, Borg B, Kerridge RK, Douglas J, Brannan J, Pretto J, Godsall MG, Beauchamp N, Allen S, Kennedy A, Wright E, Malherbe J, Ismail H, Riedel B, Melville A, Sivakumar H, Murmane A, Kenchington K, Kirabiyik Y, Gurunathan U, Stonell C, Brunello K, Steele K, Tronstad O, Masel P, Dent A, Smith E, Bodger A, Abolfathi M, Sivalingam P, Hall A, Painter TW, Macklin S, Elliott A, Carrera AM, Terblanche NCS, Pitt S, Samuels J, Wilde C, Leslie K, MacCormick A, Bramley D, Southcott AM, Grant J, Taylor H, Bates S, Towns M, Tippett A, Marshall F, Mazer CD, Kunasingam J, Yagnik A, Crescini C, Yagnik S, McCartney CJL, Choi S, Somascanthan P, Flores K, Wijeysundera DN, Beattie WS, Karkouti K, Clarke HA, Jerath A, McCluskey SA, Wasowicz M, Granton JT, Day L, Pazmino-Canizares J, Oh P, Belliard R, Lee L, Dobson K, Chan V, Brull R, Ami N, Stanbrook M, Hagen K, Campbell D, Short T, Van Der Westhuizen J, Higgie K, Lindsay H, Jang R, Wong C, McAllister D, Ali M, Kumar J, Waymouth E, Kim C, Dimech J, Lorimer M, Tai J, Miller R, Sara R, Collingwood A, Olliff S, Gabriel S, Houston H, Dalley P, Hurford S, Hunt A, Andrews L, Navarra L, Jason-Smith A, Thompson H, McMillan N, Back G, Croal BL, Lum M, Martin D, James S, Filipe H, Pinto M, Kynaston S, Pearse RM, Abbott TEF, Phull M, Beilstein C, Bodger P, Everingham K, Hu Y, Niebrzegowska E, Corriea C, Creary T, Januszewska M, Ahmad T, Whalley J, Haslop R, McNeil J, Brown A, MacDonald N, Pakats M, Greaves K, Jhanji S, Raobaikady R, Black E, Rooms M, Lawrence H, Koutra M, Pirie K, Gertsman M, Jack S, Celinski M, Levett D, Edwards M, Salmon K, Bolger C, Loughney L, Seaward L, Collins H, Tyrell B, Tantony N, Golder K, Ackland GL, Stephens RCM, Gallego-Paredes L, Reyes A, Gutierrez Del Arroyo A, Raj A, Lifford R, International, National C, Central Project Office Operations C, Committee CM, Outcome Adjudication C, International Steering C. Integration of the Duke Activity Status Index into preoperative risk evaluation: a multicentre prospective cohort study. Br J Anaesth 2020;124:261-70.